Information från ABG Sundal Collier

Här finner du information kring börsens mindre och medelstora bolag. Avsändare är ABG Sundal Collier, innehållet är inte skapat av placera.nu:s redaktion.

« Tillbaka

Midsona - Small steps forward on tougher comps

23 september 2026

<a id="bm-comp-f757a245-f9c2-483f-a6cc-bbfcc7d76c96" name="bm-comp-f757a245-f9c2-483f-a6cc-bbfcc7d76c96" class="BMCustomAnchor"></a><table><tr><td bm-component-id="f757a245-f9c2-483f-a6cc-bbfcc7d76c96" style="vertical-align: top; width:100.000000%;"><ul><li>Q3e: 1% organic growth and 5% EBIT margin</li><li>The report should answer long-term questions</li><li>Trading at NTM EV/EBITA of 7x</li></ul></td></tr></table><a id="bm-comp-4c108636-71f4-4c9f-b0a7-12b82263e03e" name="bm-comp-4c108636-71f4-4c9f-b0a7-12b82263e03e" class="BMCustomAnchor"></a><table><tr><td bm-component-id="4c108636-71f4-4c9f-b0a7-12b82263e03e" style="vertical-align: top; width:100.000000%;"><h3 class="bm-h3">Growth should return in South</h3><p style="text-align:left;">We anticipate organic growth of 1% in Q3'26, implying sales of SEK 948m and EBIT of SEK 49m, for a 5% margin. The organic growth, coupled with a 4% M&amp;A contribution and a 1% FX effect, puts top-line growth at 6%. We expect the Nordics to sustain org. growth at the same pace as in Q2 (0.5%), as we believe the warm summer likely favoured impulse consumption over dry and organic ranges. South Europe should reach 4% organic growth as comps will no longer include the old Spanish factory. We see the GM at 28% (28.7% adj. in Q3'25), roughly half on Risenta mix, which has a lower margin and still includes a transitional supply markup in COGS, and half on packaging and freight inflation into a channel with fixed pricing windows.</p><h3 class="bm-h3" style="text-align:left;">We look for long-term answers in Q3 report</h3><p style="text-align:left;">This is the first quarter with Risenta consolidated, and we will look for commentary on how much it will contribute to EBIT, specifically considering insourcing timing, the size of the transitional COGS markup, and how the organisation will be built. We also hope for a decision on the long-term plan for Spain, which since Q1 has been flagged as due soon, and look for an update on Nordic B2B after several quarters of exited contracts. On costs, we will look for how much input inflation the company intends to recover in the coming price negotiations, due to oil prices.</p><h3 class="bm-h3" style="text-align:left;">Small estimate cuts</h3><p>We cut '26e adj. EBIT by 2%, while '27e-'28e is lifted by FX. Our cuts reflect a softer Nordic category backdrop over the summer, acquired volumes that dilute mix before they contribute to profit, and input cost inflation into a channel that reprices slowly, all in the first quarter of the year against a strong comp (5% adj. EBIT margin). On our revised estimates Midsona is trading at 8x-6.5x '26e-'27e adj. EV/EBITA.</p></td></tr></table>

Senaste artiklar från alla bolag

Datum Titel Bolag Typ
2026-11-13 Clavister - Scaling up with civilian business nex... Clavister Analys
2026-11-12 Generic - Seasonality in volumes with margins hol... Generic Analys
2026-11-12 Xplora Technologies - Strong beat, but shouldn't ... Xplora Tech.. Analys
2026-11-12 Clavister - Scalability on full display Clavister Analys
2026-11-12 Generic - Softer growth but stronger earnings Generic Analys
2026-11-11 Ferronordic - The new normal Ferronordic Analys
2026-11-11 Proact - New targets include adj. EPS doubling 20... Proact Analys
2026-11-11 Ferronordic - Positive trend continues Ferronordic Analys
2026-11-10 Proact - Ahead of CMD Proact Analys
2026-11-10 G5 Entertainment - Estimates raised on lower costs G5 Entertai.. Analys
2026-11-10 Coor - Momentum building in Norway Coor Analys
2026-11-09 Generic - A broader base to grow from Generic Analys
2026-11-09 Clavister - Growth now lifts margin Clavister Analys
2026-11-09 BTS Group - Reaping the benefits of AI BTS Group Analys
2026-11-08 Cavotec - Order momentum holding, margins catchin... Cavotec Analys
2026-11-06 Inission - Strong Q3 with more to come Inission Analys
2026-11-06 Lumi Gruppen - Soft fall intake met by impressive... Lumi Gruppen Analys
2026-11-06 Ascelia Pharma - Potential FDA reread and upcomin... Ascelia Pharma Analys
2026-11-06 BTS Group - Much better than expected, stock up >10% BTS Group Analys
2026-11-06 Cavotec - Order momentum maintained Cavotec Analys